Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669615 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02669615 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 24 participants.
The verdict
NCT02669615, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for autologous stem-cell transplantation (ASCT). There will be three distinct evaluation periods in this trial: a pretreatment period, a study period and a follow-up period.
Interventions
- DRUG Melphalan HCl for injection (propylene glycol free)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2017-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669615
The ClinicalTrials.gov registry entry for NCT02669615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melphalan HCl for injection (propylene glycol free) is the first listed.
NCT02669615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669615 about?
NCT02669615 is a clinical study titled "Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation". This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for autologous stem-cell transplantation (ASCT). There will be three distinct ev...
What is the current status of trial NCT02669615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-11-01. Estimated completion is 2017-07-19.
What interventions are being tested in trial NCT02669615?
The interventions under investigation include: Melphalan HCl for injection (propylene glycol free) (DRUG).
Who is sponsoring clinical trial NCT02669615?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.